Affordable Access

Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.

Authors
Type
Published Article
Journal
Lancet (London, England)
Publication Date
Volume
359
Issue
9324
Pages
2145–2152
Identifiers
PMID: 12090979
Source
Medline
License
Unknown

Abstract

Recombinant human thrombopoietin facilitated collection of multiple units of platelets, which could be cryopreserved and reinfused to counteract severe thrombocytopenia during multicycle chemotherapy. Transfusion of autologous cryopreserved platelets derived from recombinant human thrombopoietin can provide a viable strategy to minimise the risks of allogeneic platelet transfusions and provide a long-lasting supply of platelet support.

Statistics

Seen <100 times